EUCTR2008-005885-30-SK进行中（未招募）1 期
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED,SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSIO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria prior to study entry to be eligible for enrollment into the study
- •1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- •2. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •3. Has a current diagnosis of symptomatic PAH classified by one of the following:
- •a. Idiopathic, primary or familial pulmonary arterial hypertension (IPAH, PPH, or FPAH).
- •b. PAH associated with one of the following connective tissue diseases:
- •i.Systemic sclerosis (scleroderma).
- •ii.Limited scleroderma.
- •iii.Mixed connective tissue disease.
- •iv.Systemic lupus erythematosus.
- •v.Overlap syndrome.
- •c.Exposure to drugs and toxins (eg, anorexigens, L-tryptophan, toxic rapeseed oil).
- •4.Has WHO functional class III symptoms.
- •5.Is =16 and =80 years of age.
- •6. Has a body weight of = 40 kg.
- •7. Has 6MWT distances =150 and =450 meters and distance walked within 15% of one another on two consecutive tests on different days at Screening. Both tests must be =150 and =450 meters. If the test results are not congruent, both of the Screening 6MWT should be repeated 24 hours to 2 weeks after the first attempt and the results must be within 15% of one another. If after this attempt, the subject is still not eligible, the subject will be considered a screen failure and denied entry into the study.
- •8. Had a ventilation-perfusion (V/Q) lung scan, spiral/helical/electron beam computed tomography (CT), or pulmonary angiogram within the 3 years prior to screening that shows no evidence of thromboembolic disease (normal or low probability for pulmonary embolism). If a V/Q scan is abnormal (not normal or low probability), then a confirmatory CT, angiography or selective pulmonary angiography must exclude chronic thromboembolic disease.
- •9. Had the diagnosis of PAH confirmed by a cardiac catheterization within 6 months prior to screening with the following values:
- •a.Mean pulmonary artery pressure (mPAP) >25 mm Hg (at rest).
- •b. Pulmonary capillary wedge pressure (PCWP) or left ventricular-end diastolic pressure =15 mm Hg; and
- •c. Pulmonary vascular resistance (PVR) >3 mm Hg/L/min or 240 dynes*sec/cm5.
- •10. If on calcium channel blockers, has been receiving a stable dose for at least 1 month prior to screening and maintained throughout the study.
- •11. If on vasodilators, digoxin, diuretics, spironolactone, or oxygen has been receiving a stable dose for at least 1 month prior to study screening.
- •12. If on corticosteroids, has been receiving a stable dose of =20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month prior to study screening. If receiving treatment for CTD with any other drugs, doses should remain stable for the duration of the study.
- •13. If on any medication belonging to the statin drug class eg, lovastatin, atorvastatin, has been receiving a stable dose for at least 3 months prior to study screening and maintained throughout the study.
- •14. If on warfarin (Coumadin®) or other vitamin K antagonists, has been receiving a stable treatment for at least 1 month prior to study screening; titration to target international normalized ratio (INR) is permitted.
- •15. Women of childbearing potential must be using 2 forms of medically acceptable contraception (at least 1 barrier method)
排除标准
- •Subjects presenting with any of the following will not be included in the study:
- •1. Participation in other studies (with an investigational drug or device that has not received regulatory approval) within 30 days before the current study begins (screening) and/or during study participation.
- •2. Previous exposure to an endothelin receptor antagonist (ETRA) such as sitaxsentan, bosentan or ambrisentan.
- •3. Is taking, or has an anticipated need for systemic administration (oral, intravenous (IV)) of cyclosporine A for the duration of the study.
- •4. Chronic treatment for PAH within 30 days prior to the first day of study Screening or during the study with any of the following listed below. Chronic treatment is defined as treatment administered for greater than or equal to 30 days.
- •a. Any prostacyclin or prostacyclin analogue.
- •b. Any phosphodiesterase-5 (PDE-5) inhibitor. The use of PDE-5 inhibitors as needed for erectile dysfunction is permitted as long as the subject has not taken a dose within 48 hours of an efficacy assessment. In addition, the subject should not take more than 8 sildenafil tablets, 6 vardenafil tablets or 4 tadalafil tablets per month beginning 30 days prior to screening and for the duration of the study.
- •c. Intravenous inotropes, or
- •d. Inhaled nitric oxide (excluding acute vasodilator testing during diagnostic cardiac catheterization).
- •5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure >160 mm Hg or sitting diastolic blood pressure >100 mm Hg at Screening.
- •6.Has pulmonary function tests within 3 months prior to screening that reveal evidence of significant parenchymal lung disease. Parenchymal lung disease is defined as:
- •a. Total lung capacity <70% (predicted).
- •b. Forced expiratory volume in 1 second (FEV1 ) =70% (predicted), or
- •c. Forced expiratory volume in 1 second/forced vital capacity ratio (FEV1/FVC) =60%.
- •7. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C).
- •8. Has known human immunodeficiency virus (HIV) infection, under treatment with or has anticipated need for HIV specific antiretroviral therapy.
- •9. Has hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >1.5 times the upper limit of the normal range at Screening.
- •10. Has chronic renal insufficiency as defined by serum creatinine >2.5 mg/dL at Screening or requires dialytic support.
- •11. Has a hemoglobin concentration <10 g/dL at Screening.
- •12. History of obstructive sleep apnea (treated or untreated).
- •13. History of atrial septostomy.
- •14. Has history of left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
- •a. Repaired or unrepaired congenital heart disease (CHD).
- •b. Aortic or mitral valve disease (stenosis or regurgitation) defined as more than minimum aortic insufficiency and more than moderate mitral regurgitation.
- •c. Pericardial constriction.
- •d. Restrictive or congestive cardiomyopathy.
- •e. Left ventricular ejection fraction <40% by multiple gated acquisition scan (MUGA), angiography or echocardiography (ECHO).
- •f. Left ventricular shortening fraction <22% by ECHO.
- •g. Symptomatic coronary disease with demonstrable ischemia, or
- •h. Evidence of left ventricular hypertrophy or diastolic dysfunction obtained by ECG or
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind double-dummy Phase 3 study performed at multiple study sites to evaluate the safety, efficacy and tolerability of the combinational product Carbavance (Meropenem/RPX7009) in comparison to Piperacillin/Tazobactam which is already approved in many countries to treat patients with complicated urinary tract infections, including acute pyelonephritis, in adults.complicated urinary tract infection (cUTI) or acute pyelonephritis (AP) with or without concurrent bacteremiaMedDRA version: 18.0Level: PTClassification code 10037597Term: Pyelonephritis acuteSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: HLTClassification code 10046577Term: Urinary tract infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-000545-78-HURempex Pharmaceuticals, Inc.850
尚未招募
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CARBAVANCE (MEROPENEM/RPX7009) COMPARED TO PIPERACILLIN/TAZOBACTAM IN THE TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING ACUTE PYELONEPHRITIS, IN ADULTS-N10 Acute tubulo-interstitial nephritis-N390 Urinary tract infection, site not specifiedUrinary tract infection, site not specifiedN390PER-002-15REMPEX PHARMACEUTICALS Inc. subsidiaria de propiedad total de The Medicines Company,18
进行中（未招募）
1 期
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionPulmonary Arterial HypertensionEUCTR2008-005887-14-SKPfizer Limited, Ramsgate Road, Sandwich, Kent, UK150
进行中（未招募）
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION WHO HAVE COMPLETED STUDY B1321001Pulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-005887-14-CZPfizer Ltd.150
进行中（未招募）
不适用
A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASEMedDRA version: 12.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseAlzheimer's DiseaseEUCTR2009-012456-25-DEPfizer Inc, 235 East 42nd Street, New York, NY 10017576